Dr. James W. Smithy, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 150
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Yale University School of Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 322573 -
Internal Medicine Physician
MA license 280657 · MA license 271265
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
- Memorial Hematology Lymphoma Group (216 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 150
- Services billed
- 698
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 101 | 55 |
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tafinlar (dabrafenib mesylate) | 44 |
| Mekinist (trametinib dimethyl sulfoxide) | 35 |
| Mektovi (binimetinib) | 28 |
| Braftovi (encorafenib) | 28 |
| Levothyroxine Sodium Other prescribers in New York, NY | 28 |
| Prednisone Other prescribers in New York, NY | 28 |
| Trazodone Hcl Other prescribers in New York, NY | 13 |
| Triamcinolone Acetonide Other prescribers in New York, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $2,581 in total to this clinician.
| Daiichi Sankyo Inc. | $1,626 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $955 |
| Consulting Fee | $2,581 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Jun 24, 2025 | Consulting Fee | $1,626 |
| E.r. Squibb & Sons, L.l.c. Oct 28, 2025 | Consulting Fee | $955 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $1,018,375 in research payments for these studies, mostly to the institutions running them.
- Fianlimab-cemip-ipil w/ iPET in anti-PD-1 refractory melanoma
Regeneron Pharmaceuticals, Inc. - A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo Inc. · Recruiting · NCT06172478 - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [RELAtivity-098]
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.